Concord Medical Services Holdings (FRA:C2C) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:C2C Concord Medical Services Holdings Ltd FRA:C2C
56 GF Score
Price €6.25
GF Value €9.20
! 6 Warning Signs
View Full Analysis

What is Concord Medical Services Holdings FFO per Share?

FFO per Share only applies to REITs.

FRA:C2C
56GF Score
Concord Medical Services Holdings Ltd FRA:C2C
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Concord Medical Services Holdings (FRA:C2C) Overvalued in 2026?

Based on GuruFocus' analysis, Concord Medical Services Holdings stock appears to be undervalued. The current stock price of €6.25 is trading 32.1% below its estimated GF Value™ of €9.20.

Key valuation signals for FRA:C2C:

  • FFO per Share:
  • GF Value™: €9.20 vs. price of €6.25 (32.1% below fair value)
  • GF Score™: 56/100 with 6 warning signs

No single metric tells the full story. See the FRA:C2C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Concord Medical Services Holdings Business Description

Other Exchanges CCM:USA
Address Hanwei Plaza Building, No. 7 Guanghua Road, Room A1-A5, 26th Floor, East Area, Chaoyang District, Beijing, CHN, 100020
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Geographically, the company derives revenue from PRC.
56GF Score

Get the complete analysis for FRA:C2C

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.25
Price
€9.20
GF Value